Atlas Trials

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

Clinical trial NCT05629234 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05629234
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cancer
Start date
2023-05-08
Primary completion
2027-02-22
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.